KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Other Operating Expenses: 2011-2025

Historic Other Operating Expenses for Novavax (NVAX) over the last 10 years, with Sep 2025 value amounting to $118.5 million.

  • Novavax's Other Operating Expenses rose 95.54% to $118.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.6 million, marking a year-over-year decrease of 42.49%. This contributed to the annual value of $51.9 million for FY2024, which is 84.89% down from last year.
  • Novavax's Other Operating Expenses amounted to $118.5 million in Q3 2025, which was up 673.47% from $15.3 million recorded in Q2 2025.
  • Novavax's 5-year Other Operating Expenses high stood at $434.6 million for Q3 2022, and its period low was $14.1 million during Q1 2025.
  • Its 3-year average for Other Operating Expenses is $63.1 million, with a median of $55.8 million in 2023.
  • Examining YoY changes over the last 5 years, Novavax's Other Operating Expenses showed a top increase of 124.19% in 2023 and a maximum decrease of 79.42% in 2023.
  • Over the past 4 years, Novavax's Other Operating Expenses (Quarterly) stood at $181.8 million in 2022, then decreased by 14.74% to $155.0 million in 2023, then tumbled by 76.34% to $36.7 million in 2024, then spiked by 95.54% to $118.5 million in 2025.
  • Its last three reported values are $118.5 million in Q3 2025, $15.3 million for Q2 2025, and $14.1 million during Q1 2025.